Changes in Disposition of Ezetimibe and Its Active Metabolites Induced by Impaired Hepatic Function: The Influence of Enzyme and Transporter Activities

Ningjie Xie, Hong Wang, Hua Qin, Zitao Guo, Hao Xue, Jiafeng Hu, Xiaoyan ChenPharmaceutics 2022 · DOI

TL;DR

This study investigates how liver damage affects the way the cholesterol-lowering drug ezetimibe (EZE) and its active metabolite (EZE-Ph) are processed in the body. They found that liver impairment reduces EZE's conversion to EZE-Ph in the liver but increases EZE-Ph's presence in the blood, largely due to bile acids interfering with transporters. This work is crucial for understanding how to adjust drug dosages for patients with liver disease.

What Problem Does This Paper Address?

Ezetimibe (EZE) is a widely used drug to lower cholesterol by inhibiting its absorption in the gut. After administration, EZE is converted into its active metabolite, EZE-Ph, primarily in the liver and intestine. Patients with chronic liver disease (CLD) often experience significantly higher levels of EZE and EZE-Ph in their blood. While changes in transporter activity have been implicated in EZE-Ph's altered pharmacokinetics, the precise mechanisms behind these changes, especially concerning EZE itself and the influence of the administration route, remained unclear. This paper aims to elucidate these mechanisms by investigating how impaired hepatic function affects EZE and EZE-Ph disposition, considering the roles of metabolic enzymes and transporters, and the impact of accumulated bile acids.

Methods

The researchers employed a multi-pronged approach:

  • Animal Model: They established a rat model of hepatic failure using carbon tetrachloride (CCl4) induction, a standard method for creating liver injury and fibrosis.
  • Pharmacokinetic Studies: They administered EZE orally and intravenously to both control and CCl4-induced rats and collected blood samples over time to measure EZE and EZE-Ph concentrations. They also analyzed portal and femoral vein blood to assess first-pass metabolism and hepatobiliary elimination.
  • In Vitro Metabolism Assays: Liver S9 fractions (containing both cytosolic and microsomal enzymes) from control and CCl4-induced rats were used to study the conversion of EZE to EZE-Ph. They also investigated the effect of bile acids on this metabolic process.
  • Transporter Studies:
    • Hepatocyte Uptake: Isolated rat hepatocytes were used to study the uptake of EZE and EZE-Ph.
  • Liver Slices: EZE-Ph uptake was examined in liver slices from control and CCl4-induced rats.
  • Transfected Cell Lines: HEK293 cells engineered to express specific human transporters (OATP1B1, OATP1B3, OATP2B1, OAT1, OAT3, OCT2) were used to determine EZE-Ph's transporter substrates.
  • Membrane Vesicles: Vesicles expressing human efflux transporters (MDR1, MRP2, MRP3) were used to assess EZE and EZE-Ph efflux.
  • Gene Expression Analysis: mRNA levels of key efflux transporters (Mdr1a, Mdr1b, Mrp2, Mrp3) were measured in different intestinal segments and the liver of control and CCl4-induced rats.
  • Biochemical and Histopathological Analysis: Liver function markers (ALT, AST, AKP) and liver tissue histology were assessed to confirm the successful induction of liver injury.

Datasets

Not discussed in the paper. The study primarily relies on experimental data generated from animal models and in vitro assays.

Key Insights and Ideas

  • Dual Impact of Liver Injury: Hepatic impairment doesn't affect EZE and EZE-Ph in the same way. While EZE's conversion to EZE-Ph in the liver is hindered, EZE-Ph's overall presence in the bloodstream increases.
  • Route Matters: The administration route (oral vs. intravenous) significantly influences how EZE and EZE-Ph are handled in liver disease. Oral administration leads to more pronounced changes, likely due to altered intestinal metabolism and first-pass effects.
  • Bile Acids as Disruptors: Accumulated bile acids, a common consequence of liver disease, play a critical role. They don't significantly impact EZE metabolism but actively inhibit EZE-Ph's uptake by key hepatic transporters (OATPs), leading to its accumulation.
  • Transporter Complexity: EZE-Ph is a substrate for multiple transporters, including efflux transporters (MDR1, MRP2, MRP3) and uptake transporters (OATPs), highlighting its complex disposition. EZE, on the other hand, is not significantly affected by these transporters.
  • Hepatic vs. Intestinal Metabolism: While liver injury impairs EZE's conversion to EZE-Ph in the liver, intestinal metabolism of EZE appears less affected.

Key Results

  • Increased Exposure: In CCl4-induced rats, oral EZE administration led to an 11.1-fold increase in EZE exposure and a 4.4-fold increase in EZE-Ph exposure. Intravenous administration resulted in a 2.1-fold increase in EZE and a substantial 16.4-fold increase in EZE-Ph.
  • Reduced Hepatic Metabolism: EZE to EZE-Ph conversion in CCl4-induced rat liver S9 fractions decreased concentration-dependently, while intestinal metabolism remained unchanged.
  • Transporter Involvement: EZE-Ph was identified as a substrate for OATP1B1, OATP1B3, OATP2B1, and OAT3, with OATP1B3 being the major hepatic uptake transporter. EZE-Ph was also a substrate for MDR1, MRP2, and MRP3 efflux transporters.
  • Bile Acid Inhibition: Bile acids significantly inhibited EZE-Ph uptake by OATPs, with GCDCA and TCDCA showing particularly potent inhibition (IC50 values of 15.1 and 7.94 µM, respectively, for OATP1B3).
  • Efflux Transporter Changes: Hepatic impairment led to increased Mdr1b and Mrp3 mRNA levels in the liver, while Mrp2 expression decreased. Intestinal Mdr1a and Mdr1b mRNA levels increased, but Mrp2 decreased.

Limitations and Future Work

  • Animal Model: While CCl4-induced liver injury is a well-established model, it may not perfectly replicate the complex pathology of human chronic liver disease.
  • Interspecies Differences: The study used rat models and human transporter cell lines. While valuable, direct extrapolation to human clinical scenarios requires careful consideration of interspecies differences in transporter expression and function.
  • Bile Acid Concentrations: The study demonstrated that bile acids inhibit EZE-Ph uptake. Future work could further investigate the precise in vivo concentrations of these bile acids in different stages of liver disease and their direct correlation with EZE-Ph pharmacokinetics.
  • Clinical Translation: The findings provide a strong mechanistic basis for observed changes in EZE pharmacokinetics in CLD patients. Further clinical studies are warranted to confirm these findings and guide personalized dosing strategies.
  • Drug Interactions: The study highlights the impact of endogenous compounds (bile acids) on drug disposition. Future research could explore potential interactions with other co-administered drugs that might also be substrates or inhibitors of these transporters.

Summary updated

Abstract

Ezetimibe (EZE) is a selective cholesterol absorption inhibitor. Hepatic impairment significantly increases the systemic exposure of EZE and its main active phenolic glucuronide, EZE-Ph. Although changes in efflux transporter activity partly explain the changes in EZE-Ph pharmacokinetics, the causes of the changes to EZE and the effects of the administration route on EZE-Ph remain unclear. A carbon tetrachloride (CCl<sub>4</sub>)-induced hepatic failure rat model was combined with in vitro experiments to explore altered EZE and EZE-Ph disposition caused by hepatic impairment. The plasma exposure of EZE and EZE-Ph increased by 11.1- and 4.4-fold in CCl<sub>4</sub>-induced rats following an oral administration of 10 mg/kg EZE, and by 2.1- and 16.4-fold after an intravenous injection. The conversion of EZE to EZE-Ph decreased concentration-dependently in CCl<sub>4</sub>-induced rat liver S9 fractions, but no change was observed in the intestinal metabolism. EZE-Ph was a substrate for multiple efflux and uptake transporters, unlike EZE. In contrast to efflux transporters, no difference was seen in the hepatic uptake of EZE-Ph between control and CCl<sub>4</sub>-induced rats. However, bile acids that accumulated due to liver injury inhibited the uptake of EZE-Ph by organic anion transporting polypeptides (OATPs) (glycochenodeoxycholic acid and taurochenodeoxycholic acid had IC<sub>50</sub> values of 15.1 and 7.94 μM in OATP1B3-overexpressed cells). In conclusion, the increased plasma exposure of the parent drug EZE during hepatic dysfunction was attributed to decreased hepatic glucuronide conjugation, whereas the increased exposure of the metabolite EZE-Ph was mainly related to transporter activity, particularly the inhibitory effects of bile acids on OATPs after oral administration.
BibTeX
@inproceedings{xie2022changes,
  author = {Ningjie Xie and Hong Wang and Hua Qin and Zitao Guo and Hao Xue and Jiafeng Hu and Xiaoyan Chen},
  title = {{Changes in Disposition of Ezetimibe and Its Active Metabolites Induced by Impaired Hepatic Function: The Influence of Enzyme and Transporter Activities}},
  booktitle = {Pharmaceutics},
  year = {2022},
  doi = {10.3390/pharmaceutics14122743},
}
Figure